Introduction: VIP Beyond the Gut
Vasoactive intestinal peptide (VIP) may be named after its original discovery site — the gastrointestinal tract — but researchers have since identified it as one of the most broadly active neuropeptides in the human body. This 28-amino acid signaling molecule participates in neuroinflammation control, circadian rhythm synchronization, immune modulation, and neuroprotection across multiple CNS disease models.
For research applications, VIP has attracted attention as a potential therapeutic candidate in neurodegeneration, chronic inflammatory conditions, and circadian dysregulation. With 33 active listings on Peptides.SO, interest is accelerating — yet practical dosing and reconstitution guidance for research contexts remains sparse on most platforms.
This protocol guide synthesizes available literature, community-documented protocols, and pharmacokinetic data to provide researchers with a structured reference for VIP use in preclinical contexts.
> Research Use Only Disclaimer: VIP is not FDA-approved for the research applications described in this guide. All dosage information is derived from published preclinical literature and research community protocols. This guide is for educational and research purposes only. Not for human use.
---
Research Applications Overview
Neuroinflammation and Neuroprotection
VIP's most documented research application is in reducing neuroinflammation. Multiple studies demonstrate that VIP inhibits activated microglia — the brain's resident immune cells — from releasing pro-inflammatory mediators including TNF-alpha, IL-1beta, and nitric oxide.
A landmark study (PMID: 12923064) demonstrated that VIP prevents neuronal cell death under inflammatory conditions by deactivating microglia. This research established VIP as a candidate "microglia-deactivating factor" — a classification with implications for traumatic brain injury, Alzheimer's disease, and Parkinson's research contexts.
More recent work (PMID: 38382910) confirmed that both synthetic VIP and lentiviral VIP-transduced microglia protected neuronal cells from toxin-induced degeneration, supporting the translational relevance of VIP's anti-neuroinflammatory mechanism.
Circadian Rhythm Regulation
VIP serves as the primary neurotransmitter in the suprachiasmatic nucleus (SCN) — the brain's master circadian clock. VIP-VPAC2 signaling synchronizes the individual clock neurons of the SCN into a coherent rhythm. In VIP-deficient mouse models, circadian disorganization is severe and persistent, illustrating VIP's indispensable role in circadian architecture.
Researchers studying circadian rhythm disorders, shift-work models, or sleep disruption protocols frequently include VIP as a reference compound or direct experimental agent.
Immune Modulation
VIP signals through VPAC1 receptors expressed broadly on immune cells. Activation leads to increased intracellular cAMP, downstream PKA phosphorylation, and CREB-mediated gene expression that shifts cytokine profiles toward anti-inflammatory phenotypes. VIP has been studied in autoimmune models including multiple sclerosis, rheumatoid arthritis, and Crohn's disease analogs (PMC8473805).
Pulmonary Research
VIP is a potent pulmonary vasodilator and bronchodilator. Its endogenous expression in lung tissue led to investigation as a therapeutic in pulmonary arterial hypertension — including as a synthetic analog (aviptadil/RLF-100) that reached clinical trials. Researchers studying pulmonary vascular resistance or alveolar inflammation sometimes reference VIP protocols from this clinical literature.
---
Reconstitution: Step-by-Step Protocol
Supplies Required
- •VIP lyophilized powder (commonly supplied as 5 mg or 10 mg vials)
- •Bacteriostatic water (BAC water) — preferred for multi-dose vials
- •Sterile water for injection — acceptable for single-use
- •Insulin syringe (29-31 gauge)
- •Alcohol wipes
Reconstitution Protocol: 5 mg Vial
| Step | Action |
|---|---|
| 1 | Wipe the vial cap with an alcohol swab and allow to dry |
| 2 | Draw 5 mL of bacteriostatic water into a syringe |
| 3 | Inject the BAC water slowly down the inside wall of the vial (do not spray directly onto the powder) |
| 4 | Gently swirl — do not shake — until the powder is fully dissolved |
| 5 | Allow 2-3 minutes for complete dissolution |
| 6 | Final concentration: 1 mg/mL (1,000 mcg/mL) |
Reconstitution Protocol: 10 mg Vial
For a 10 mg vial reconstituted with 3 mL bacteriostatic water:
- •Final concentration: 3.33 mg/mL (3,333 mcg/mL)
For a 10 mg vial reconstituted with 10 mL bacteriostatic water:
- •Final concentration: 1 mg/mL (1,000 mcg/mL) — easier dose calculations
Calculating Dose Volumes
Using a 1 mg/mL (1,000 mcg/mL) concentration as baseline:
| Research Dose | Volume to Draw |
|---|---|
| 25 mcg | 0.025 mL (2.5 units on insulin syringe) |
| 50 mcg | 0.05 mL (5 units on insulin syringe) |
| 100 mcg | 0.1 mL (10 units on insulin syringe) |
| 200 mcg | 0.2 mL (20 units on insulin syringe) |
> Peptide Reconstitution Calculator: For custom dilution ratios and dose calculations, use the Peptide Reconstitution & Dosage Calculator.
---
Research Dosing Protocols from Literature
VIP has a short biological half-life (approximately 2 minutes in plasma due to rapid peptidase cleavage), which drives the need for either continuous infusion, frequent dosing, or local delivery routes. Research protocols have adapted accordingly.
Subcutaneous Injection Protocols
Subcutaneous administration is the most common research route in community-documented protocols. It allows controlled systemic delivery with modest CNS penetration relative to intranasal routes.
Standard Research Protocol:
- •Dose: 50-100 mcg per injection
- •Frequency: Twice daily (AM and PM)
- •Duration: 8 weeks on / 8 weeks off cycle
- •Injection sites: Abdomen, thigh, or upper arm
Conservative Starting Protocol:
- •Dose: 50 mcg once daily
- •Frequency: Single AM administration
- •Duration: 2-week observation period before titration
Higher-Range Protocol (from literature):
- •Dose: 100-300 mcg per injection
- •Note: Higher doses associated with greater risk of transient hypotension
Subcutaneous doses in the literature typically span 50-300 mcg, with most community-reported protocols clustering at 100 mcg twice daily as a practical research benchmark.
Intranasal Administration Protocols
Intranasal delivery is particularly relevant to neuroprotection research because it enables direct nose-to-brain transport, partially bypassing the blood-brain barrier. The landmark pharmacodynamics study (PMID: 23444784) evaluated intranasal VIP in an Alzheimer's model (Abeta25-35 injection), finding that a 200 mcg/mL concentration improved spatial memory deficits to statistically normal levels in treated mice.
Intranasal VIP reaches detectable plasma levels within 5-15 minutes — significantly faster than subcutaneous injection (30-90 minutes), which has implications for timing-sensitive circadian rhythm research.
Intranasal Dosing Reference:
| Parameter | Typical Range |
|---|---|
| Concentration | 50-200 mcg per spray |
| Daily total | 50-200 mcg/day |
| Delivery | Compounded nasal spray |
| Onset | 5-15 minutes to detectable plasma levels |
Shoemaker CIRS Protocol Context:
Clinicians following the Shoemaker protocol for Chronic Inflammatory Response Syndrome (CIRS) use compounded intranasal VIP as a late-stage therapeutic — typically as the final step after visual contrast sensitivity (VCS), biomarker normalization, and remediating exposure. This context is distinct from general research dosing; researchers studying CIRS models should note that VIP is positioned at the end of a multi-step correction sequence in this framework.
---
Administration Routes: Research Comparison
| Parameter | Intranasal | Subcutaneous |
|---|---|---|
| Onset | 5-15 min | 30-90 min |
| CNS penetration | Higher (nose-to-brain pathway) | Lower (systemic first) |
| Dose precision | Lower (dependent on nasal deposition) | Higher |
| Preparation | Compounded spray required | Reconstituted vial |
| Half-life consideration | Same (~2 min plasma) | Same (~2 min plasma) |
| Best for | CNS/circadian research | Systemic immune/pulmonary research |
Route selection guidance:
- •Neuroinflammation and cognitive research: Intranasal preferred for direct CNS access
- •Immune modulation and pulmonary research: Subcutaneous provides more reliable systemic exposure
- •Circadian synchronization research: Intranasal — timing-sensitive models benefit from faster onset
---
Stability and Storage
VIP is sensitive to temperature, light, and mechanical agitation. Proper storage is critical to maintain peptide integrity throughout the research protocol.
Lyophilized (Unreconstituted) Storage
| Condition | Stability |
|---|---|
| -20 degrees C (freezer) | 2+ years |
| 2-8 degrees C (refrigerator) | Up to 12 months |
| Room temperature | Not recommended; degradation accelerates |
Reconstituted Storage
| Condition | Stability |
|---|---|
| 2-8 degrees C (refrigerator) | 14-21 days |
| -20 degrees C | Up to 3 months (avoid repeated freeze-thaw) |
| Light exposure | Minimize; store in amber vial or wrapped |
Handling notes:
- •Never shake a reconstituted VIP vial — use gentle swirling only
- •If the solution appears cloudy or contains particles, discard
- •Each freeze-thaw cycle degrades peptide integrity; minimize cycling by aliquoting
---
VIP vs. Selank vs. Semax: Brief Research Comparison
Researchers investigating neuroprotective and cognitive-enhancing peptides often evaluate VIP alongside Selank and Semax. Each operates through distinct mechanisms:
| Peptide | Primary Mechanism | Key Research Area | Route |
|---|---|---|---|
| VIP | VPAC1/VPAC2 -> cAMP/CREB; anti-inflammatory microglial signaling | Neuroinflammation, circadian, CIRS | Intranasal, SubQ |
| Selank | Tuftsin analog; IL-6 and BDNF modulation | Anxiolytic, immune, cognitive stabilization | Intranasal |
| Semax | ACTH analog; BDNF upregulation | Acute cognitive enhancement, neuroprotection | Intranasal |
Key distinctions:
- •VIP addresses upstream neuroinflammation through microglial deactivation — it is the only one of the three with direct circadian synchronization activity via SCN VPAC2 signaling
- •Semax has more robust data on acute cognitive enhancement and BDNF upregulation (Semax Dosage Guide)
- •Selank is better characterized for anxiolytic and immunomodulatory applications without the cardiovascular activity VIP carries (Selank Dosage Guide)
For researchers designing multi-peptide protocols, VIP's anti-inflammatory properties may complement Semax's neurotrophic profile, though combination data in preclinical models remains limited.
---
Key Research Findings
Alzheimer's Disease Models:
- •VIP (200 mcg/mL intranasal) rescued spatial memory deficits in Abeta25-35-injected mice to statistically normal levels (PMID: 23444784)
- •Fatty VIP analogue delivered intranasally prevented cholinergic blockade-related learning impairments (PMID: 8552653)
- •VIP enhanced microglial phagocytosis of fibrillar beta-amyloid in APP/PS1 transgenic models
Neuroinflammation:
- •VIP inhibits microglial TNF-alpha, IL-1beta, and nitric oxide production, preventing inflammation-induced neurodegeneration (PMID: 12923064)
- •Synthetic VIP-treated microglia protected neurons against toxin-induced degeneration in 2024 research (PMID: 38382910)
- •NF-kappaB suppression in microglial models: 40-60% reduction in activation markers
Circadian Research:
- •VIP is essential for SCN coherence; VIP-knockout models display severe circadian disorganization
- •VPAC2-selective agonism is sufficient to restore circadian pacemaking in VIP-deficient neurons
Receptor Pharmacology:
- •VPAC1 and VPAC2 both couple to Gs -> adenylate cyclase -> cAMP -> PKA -> CREB activation
- •VPAC2 is the primary circadian receptor; VPAC1 dominates in peripheral immune tissues
- •VIP also activates PAC1 at higher concentrations, overlapping with PACAP signaling pathways (PMC8473805)
---
Frequently Asked Questions
What is the typical research dose of VIP?
Most preclinical protocols use 50-200 mcg per dose. The most commonly referenced research dosage is 100 mcg subcutaneously twice daily or 50-200 mcg/mL intranasally. Dose selection depends on the research model, route, and outcome measure.
How is VIP reconstituted for research use?
Add bacteriostatic water to the lyophilized vial slowly along the vial wall. A 5 mg vial + 5 mL BAC water yields 1 mg/mL (1,000 mcg/mL), making dose calculations straightforward on an insulin syringe.
How long is reconstituted VIP stable?
14-21 days at 2-8 degrees C. Protect from light and avoid shaking. For longer storage, aliquot and freeze at -20 degrees C, minimizing freeze-thaw cycles.
Why does VIP have such a short half-life?
VIP is rapidly cleaved by tissue peptidases (including neutral endopeptidase 24.11 and dipeptidyl peptidase IV) with a plasma half-life of approximately 2 minutes. Research protocols compensate with divided dosing, sustained infusion models, or more stable analogs.
Is intranasal or subcutaneous VIP better for CNS research?
Intranasal is generally preferred for CNS-targeted research due to direct nose-to-brain transport. Subcutaneous is preferable when systemic immune or pulmonary effects are the research endpoint.
What safety considerations apply in VIP research?
Transient hypotension is the primary concern, especially at higher doses or in low blood pressure models. Facial flushing, diarrhea, and nasal irritation (intranasal) are also observed. Lipase monitoring is recommended in protocols involving repeated systemic dosing.
Is VIP the same as aviptadil (RLF-100)?
Aviptadil is a synthetic analog of human VIP that reached Phase III clinical trials for ARDS and pulmonary hypertension. It shares the same receptor targets (VPAC1, VPAC2) but is a distinct pharmaceutical formulation not equivalent to research-grade VIP peptide.
---
Internal Links
- •VIP Price Comparison & Research Suppliers
- •Semax Dosage Protocol Guide — ACTH analog neuroprotection
- •Selank Dosage Protocol Guide — Tuftsin analog anxiolytic
- •Semax vs Selank Comparison
- •VIP Research Profile: Pleiotropic Neuropeptide Overview
- •Peptide Reconstitution Calculator
- •How to Reconstitute Peptides
---
This content is intended for research and educational purposes only. VIP is not FDA-approved for the applications described. Always conduct research in accordance with applicable regulations and institutional guidelines.